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Abstract
From 2002 to 2006, 35 of 73 multidrug-resistant Pseudomonas
aeruginosa isolates from different wards at Charles Nicolle hospi-
tal of Tunis were positive for class B carbapenemase (using the
imipenem–EDTA test), owing to a blaVIM-2 gene cassette in a
class 1 integron. Twenty-three isolates additionally produced the
extended-spectrum b-lactamase SHV2a. DNA sequences imme-
diately surrounding blaSHV2a shared extensive identity with a
Klebsiella pneumoniae plasmid sequence. Despite belonging to the
same chromosomal type, as shown by pulsed-ﬁeld gel electro-
phoresis (PFGE), the VIM-2 producing P. aeruginosa isolates
prevalent at Charles Nicolle hospital displayed a diversity of
VIM-2-carrying integrons.
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Carbapenems are among the drugs of choice for the
treatment of infections due to multidrug-resistant (MDR)
Pseudomonas aeruginosa. However, their efﬁcacy is being
increasingly compromised by the emergence of P. aeruginosa
strains producing metallo-b-lactamases (MBLs) [1], which are
implicated in large outbreaks, as described in Greece, Italy,
Canada, Korea and Kenya [2–6]. We report the ﬁrst molec-
ular characterization of Tunisian MBL-producing P. aeruginosa
isolates, some of which were also extended-spectrum
b-lactamase producers.
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A total of 73 MDR P. aeruginosa isolates (deﬁned as being
resistant to at least three different families of antibiotics)
were collected at Charles Nicolle hospital of Tunis. Among
these isolates, 35 were positive according to the EDTA disk
synergy test (AB Biodisk, Solna, Sweden), suggesting the
presence of a class B enzyme. The frequency of MBL-produc-
ing P. aeruginosa among imipenem-resistant isolates was sta-
ble between 2002 and 2004, but increased dramatically from
2005: 1% (1/99) in 2002, 1% (1/111) in 2003, 1% (1/85) in
2004, 25% (16/65) in 2005, and 28% (16/57) in 2006. This is
consistent with the worldwide increase in the frequency of
MBL producers among P. aeruginosa clinical isolates, particu-
larly in Europe [1–4,7,8]. MICs of ticarcillin, ticarcillin–clavul-
anic acid (2 mg/L), aztreonam, ceftazidime, imipenem,
meropenem and rifampin were determined using the dilution
method on Mueller–Hinton agar, according to CLSI guide-
lines [9]. The MIC determinations showed high levels of
resistance to all b-lactams (Table 1).
In order to determine whether the MBL-producing iso-
lates were clonally related, pulsed-ﬁeld gel electrophoresis
(PFGE) of SpeI-digested genomic DNA samples was per-
formed with a CHEF-DRIII apparatus (Bio-Rad Laboratories,
Hercules, CA, USA). PFGE patterns were interpreted
according to the criteria of van Belkum et al. [10]. The distri-
bution of the PFGE patterns is shown in Table 1. Only one
PFGE type was found, suggesting a clonal outbreak, including
three subtypes differing from each other by one to four
bands.
PCR ampliﬁcation with primers for blaTEM, blaSHV, blaCTX-M,
blaIMP, blaVIM and blaVIM-2 (Table S1) was performed to further
investigate the presence of b-lactamase genes. Sequencing of
the ampliﬁed fragments conﬁrmed the presence of blaVIM-2 in
all isolates. Many studies have reported that VIM-2 is the most
prevalent type of MBL in various Mediterranean countries,
i.e. Italy, Greece and France [1–3,7], but this is the ﬁrst report
of the VIM-2 MBL in P. aeruginosa from Tunisia and the second
from the African continent [6].
PCR and sequencing revealed that SHV-2a was the only
class A enzyme present in our set of isolates (Table 1).
SHV-2a has been previously described in a clinical isolate of








year) Specimen Imp Mem Tic Tcc Azt Caz Rif SHV-2
Gene cassette
array of class 1
integrons containing
an MBL gene PFGE
10 50/M ENT 09/08/2005 Pus >2048 128 >2048 >1024 64 64 256 + blaVIM-2–arr6 A2
12 50/M ICU 04/07/2005 Blood >2048 2048 >2048 >1024 64 512 512 + blaVIM-2–arr6 A2
20 45/F Surgery 24/04/2006 Catheter >2048 128 >2048 >1024 64 64 512 + blaVIM-2–arr6 A2
21 50/F Surgery 10/05/2006 Catheter >2048 128 2048 >1024 64 64 512 + blaVIM-2–arr6 A2
22 41/M Surgery 20/05/2006 Blood >2048 64 >2048 >1024 128 256 512 + blaVIM-2–arr6 A2
25 45/M Surgery 02/06/2006 Blood >2048 128 >2048 >1024 128 512 1024 + blaVIM-2–arr6 A2
26 31/M Surgery 10/06/2006 Catheter >2048 16 >2048 >1024 128 512 1024 + blaVIM-2–arr6 A2
27 45/M Surgery 10/06/2006 BS >2048 32 >2048 >1024 128 64 512 + blaVIM-2–arr6 A2
28 45/M Surgery 12/06/2006 Urine >2048 64 2048 512 128 32 512 + blaVIM-2–arr6 A2
29 23/M Surgery 24/06/2006 Urine >2048 1024 >2048 >1024 128 64 1024 + blaVIM-2–arr6 A2
30 40/F Surgery 03/07/2006 Pus >2048 128 >2048 >1024 128 64 512 + blaVIM-2–arr6 A2
31 65/M Surgery 03/08/2006 Catheter >2048 32 2048 1024 128 64 512 + blaVIM-2–arr6 A2
32 65/M Surgery 12/08/2006 Blood >2048 32 >2048 >1024 64 256 512 + blaVIM-2–arr6 A2
34 45/M Surgery 04/07/2006 Blood 2048 64 >2048 >1024 128 512 512 + blaVIM-2–arr6 A2
35 43/F Surgery 14/10/2006 BS >2048 64 >2048 >1024 256 512 1024 + blaVIM-2–arr6 A2
1 1/M Paediatrics 12/11/2002 Urine >2048 256 2048 >1024 64 512 <32 ) blaVIM-2–aacA7–aacA4 A1
2 2/M Paediatrics 03/03/2003 Urine >2048 128 2048 >1024 64 256 128 ) blaVIM-2–aacA7–aacA4 A1
11 59/M Pneumology 19/08/2005 BS >2048 128 2048 512 16 16 <32 + blaVIM-2–aacA7–aacA4 A3
13 59/M ICU 14/04/2005 Blood >2048 64 >2048 >1024 64 512 <32 ) blaVIM-2–aacA7–aacA4 A3
14 42/F ICU 23/05/2005 BS >2048 256 >2048 >1024 64 512 <32 ) blaVIM-2–aacA7–aacA4 A3
15 50/M ICU 07/07/2005 Catheter >2048 256 2048 >1024 64 64 <32 ) blaVIM-2–aacA7–aacA4 A3
17 28/M ICU 23/07/2005 Pus >2048 2048 2048 >1024 32 64 <32 ) blaVIM-2–aacA7–aacA4 A3
18 65/M Surgery 01/07/2005 BS >2048 2048 >2048 >1024 64 256 <32 ) blaVIM-2–aacA7–aacA4 A3
19 23/M ICU 01/07/2005 Blood >2048 256 >2048 >1024 64 512 <32 ) blaVIM-2–aacA7–aacA4 A3
23 61/M ICU 24/05/2006 Blood >2048 64 >2048 >1024 128 512 <32 ) blaVIM-2–aacA7–aacA4 A3
24 61/M ICU 23/05/2006 BS >2048 64 >2048 >1024 128 512 <32 ) blaVIM-2–aacA7–aacA4 A3
3 60/M Surgery 09/11/2004 Pus >2048 256 >2048 512 64 256 256 + blaVIM-2–aadB–arr6 A2
4 56/F Surgery 07/03/2005 BS >2048 128 >2048 >1024 64 256 512 + blaVIM-2–aadB–arr6 A2
6 69/F Surgery 24/06/2005 Blood >2048 2048 2048 512 256 64 512 + blaVIM-2–aadB–arr6 A2
7 52/M ICU 30/06/2005 Blood >2048 2048 >2048 >1024 64 64 256 + blaVIM-2–aadB–arr6 A2
16 55/F Surgery 30/06/2005 Blood >2048 2048 >2048 >1024 128 128 512 + blaVIM-2–aadB–arr6 A2
33 74/M Surgery 09/10/2006 BS >2048 64 >2048 >1024 128 512 512 + blaVIM-2–aadB–arr6 A2
5 39/F ICU 22/09/2005 Catheter 2048 256 >2048 >1024 64 64 <32 ) blaVIM-2–aacA7 A3
8 79/M ICU 04/08/2005 Catheter >2048 1024 >2048 >1024 64 512 <32 + blaVIM-2–aacA7 A3
9 79/M ICU 05/08/2005 Catheter 2048 128 >2048 >1024 64 512 <32 ) blaVIM-2–aacA7 A3
BS, bronchial secretions; ICU, intensive-care unit; MBL, metallo-b-lactamase; PFGE, pulsed-ﬁeld gel electrophoresis; Imp, imipenem; Mem, meropenem; Tic, ticarcillin; Tcc,
ticarcillin–clavulanic acid; Azt, aztreonam; Caz, ceftazidime; Rif, rifampin.
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P. aeruginosa recovered from a French patient hospitalized in
Tunisia [11]. The coexistence of class A and class B enzymes
in the same isolate has been described in Klebsiella pneumo-
niae isolates from Tunisia [12]. Many studies have described
the association between members of these two classes of
enzymes: VIM-1 and SHV-5 [13] and VIM-4 and SHV-12 [14]
in Enterobacteriaceae, and PER-1 and VIM-2 in P. aeruginosa
[15,16].
To analyse the genetic support of these b-lactamase genes,
conjugational transfers were performed with P. aeruginosa
PAO38 rifR or Escherichia coli J53-2 rifR as the recipient
strains, with selection on aztreonam (4 mg/L), or ticarcillin
(125 mg/L), or imipenem (2 mg/L) and rifampin (250 mg/L).
Isolates 8 and 11 (with rifampin MICs <32 mg/L), which pro-
duced both VIM-2 and SHV-2a, were tested as donor strains.
Transfer experiments were unsuccessful for both genes.
DNA fragments obtained from partially Sau3A-digested
genomic DNA of two representative isolates (1 and 4) were
ligated into the vector pACYC184 digested with BamHI. E. coli
DH10B transformants were selected on Mueller–Hinton
agar supplemented with chloramphenicol (50 mg/L) and
ticarcillin (125 mg/L). The inserted DNA fragments and the
genetic organization of blaVIM-2 and blaSHV-2a were investigated
by PCR and sequencing, using the primers listed in Table S1.
First, the cloned 5599-bp fragment from isolate 1
(D1463a) was found to carry a class 1 integron. The cassette
region contained blaVIM-2, aacA7 and aacA4 (Fig. 1a). By PCR
mapping and sequencing, the same genetic organization was
found for ten additional isolates (Table 1). In the upstream
part of this integron, an insertion sequence element, ISPa7,
was bracketed by two 17-bp inverted repeats, as described
previously in In70 [3].
On the basis of PCR mapping, all other isolates also har-
boured ISPa7, intI1, and blaVIM-2. This cassette was found in
the ﬁrst position of the integron, which indicates that it was
the most recently acquired resistance gene. PCR with reverse
primers speciﬁc to the 3¢-CS of class 1 integrons gave PCR
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FIG. 1. Schematic representation of the genetic environment of blaVIM-2 (a) and blaSHV-2a (b) in clinical isolates of carbapenem-resistant Pseudo-
monas aeruginosa at the Charles Nicolle Hospital in Tunis. (a) Four different genetic organizations of integrons bearing blaVIM-2, with indication of
accession number, strain and isolate. Regions with 100% identity are shown in grey. (b) Genetic context of blaSHV-2a in P. aeruginosa strain B2781
from Tunisia (isolate 4) and comparison with previously reported relevant genetic organizations (with indication of accession number, strain, and
plasmid). Regions related to the Klebsiella pneumoniae chromosome are shown in dark grey; regions with 100% identity with genetic structures
involved in blaSHV-type mobilization are shown in light grey.
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cassette was found to be part of an integron containing two
additional cassettes: aadB and arr6, a novel rifampin ADP ri-
bosyl transferase gene (Fig. 1a). Indeed, ARR-6 shares 75–
80% amino acid identity with ARR-2, ARR-3, ARR-4 and
ARR-5. The remaining 18 isolates displayed a novel structure
for class I integrons involving two pairs of cassettes: either
blaVIM-2 and aacA7, or blaVIM-2 and arr6 (Table 1; Fig. 1a).
These combinations of gene cassettes are different from
those reported in Kenya [6]. Analysis of integron structures
yielded identical proﬁles in all isolates of PFGE subtype A1
and in some isolates of subtype A3, suggesting a conserved
structure of the blaVIM-2-containing integrons. However, iso-
lates of subtype A2 were shown to contain two new integ-
ron structures.
All isolates producing ARR-6 showed high levels of resis-
tance to rifampin (MIC range 256–1024 mg/L), whereas the
MIC of rifampin was <32 mg/L for all others isolates except
one (128 mg/L) (Table 1). Using the IntlI-Vim-2-for and the
3¢CS primers and the Topo XL PCR cloning kit (Invitrogen,
Cergy-Pontoise, France), the 2-kb PCR product (obtained
from isolate 10; Table 1) was cloned into electrocompetent
E. coli TOP10. After selection on kanamycin (50 mg/L) and
ticarcillin (125 mg/L), the recombinant clone harboured
blaVIM-2 (PCR-positive) and showed a high level of resistance
to rifampin (MIC >256 mg/L).
Second, the cloned 3373-bp fragment from isolate 4
(B2781) contained an IS26 insertion element, blaSHV-2a, and
Tn1721; the sequences immediately upstream and down-
stream from blaSHV-2a showed 100% DNA identity with parts
of the plasmid pMPA2a from K. pneumoniae KpZU-3 [17]
and with the plasmid pPL20 (pPa-1) from P. aeruginosa RP-1
[11] (Fig. 1b). The more distantly related sequences down-
stream from blaSHV-2a had 100% identity with Tn1721, a
transposon often found in Enterobacteriaceae [18]. On the
basis of PCR mapping, all isolates harbouring blaSHV-2a had
this same structure.
This article describes a high frequency of VIM-2 among
MDR P. aeruginosa isolates from Tunisia, as well as the
presence of new integrons encoding a VIM-2-type MBL and
the detection of a novel gene cassette containing a rifampin
resistance gene in some of these isolates. The nucleotide
sequences have been submitted to the EMBL/GenBank under
accession numbers AM774408, AM988778, AM988779,
FM897214, and FM955585.
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Abstract
Benign acute childhood myositis (BACM) is a rare transient con-
dition usually occurring at the early convalescent phase of a viral
upper respiratory tract illness, normally inﬂuenza A, and, more
frequently, inﬂuenza B infection. It is characterized by acute-
onset difﬁculty in walking as a result of severe bilateral calf pain
and by elevated muscle enzymes including creatinine kinase. It is
self-limiting because there is rapid full recovery usually within
1 week. We describe the ﬁrst case of BACM in association with
the new pandemic inﬂuenza A (H1N1) virus infection in an 11-
year-old boy from Cyprus. The child had the typical clinical and
laboratory characteristics of this clinical syndrome. Prompt diag-
nosis of this clinical entity is essential to prevent unnecessary
investigations and therapeutic interventions and to reassure the
patient and parents of the excellent prognosis.
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Benign acute childhood myositis (BACM) is a rare, self-
limiting muscle disorder mainly affecting boys of school age.
Clinically, it is characterized by the sudden onset of calf pain
and muscle tenderness, and a refusal to walk and/or difﬁculty
in walking. Serum creatinine kinase (CK) is elevated in most
cases. The clinical manifestations usually follow the initial
phase of an acute upper respiratory tract illness, most
frequently associated with inﬂuenza viruses, particularly
inﬂuenza B. Therefore, most of the cases reported in the
literature have been encountered during epidemics of
inﬂuenza [1–4]. Typically, the illness lasts for brief periods of
time, usually up to 1 week, and adults are very rarely
affected [5].
During the current pandemic of inﬂuenza A (H1N1) virus
infection, various complications have been described in chil-
dren and adults, including bacterial superinfections and neu-
rological complications [6–9]. In one report of hospitalized
cases with serious pneumonia and respiratory failure from
Mexico, increased CK serum levels were detected in 62% of
patients [10]. However, there have been no reported cases
with the clinical syndrome of benign acute myositis associ-
ated with the new inﬂuenza A virus in children.
We present a case of BACM associated with the new
inﬂuenza A (H1N1) virus infection in an 11-year-old boy
from Cyprus. To the best of our knowledge, this is the ﬁrst
case of this clinical syndrome being reported in association
with the current inﬂuenza A pandemic.
On 5 September 2009, a previously healthy 11-year-old
boy was admitted to the Special Ward for inﬂuenza A infec-
tion of the Paediatric Department of the Archbishop Makari-
os Hospital, the main referral hospital in Nicosia, the capital
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